Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Doering

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Gynecologic Oncology|November 25, 1998
Metastatic dermatofibrosarcoma protuberans of the vulvaT M Soergel, D L Doering, D O'connor
Journal of Clinical Laboratory Analysis|January 1, 1995
Comparison of cathepsin D determinations in human carcinomas by enzyme immunoassay and immunoradiometric assayR M Shaheen, S Miseljic, D L Doering, et al.
Gynecologic Oncology|September 1, 1996
Vulvar eccrine porocarcinomaW A Katsanis, D L Doering, J R Bosscher, et al.
Gynecologic Oncology|January 1, 1996
Aberrations in normal systemic lipid metabolism in ovarian cancer patientsC Gercel-Taylor, D L Doering, F B Kraemer, et al.
Gynecologic Oncology|January 4, 2001
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancerC Tecimer, D L Doering, L J Goldsmith, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancerC. Tecimer, D. L. Doering, L. J. Goldsmith, et al.
Gynecologic Oncology|April 1, 1997
Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell linesR K Gibb, D D Taylor, T Wan, et al.
Cancer|February 15, 1996
Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteriJ S Sanfilippo, S Miseljic, A R Yang, et al.
Cancer|August 15, 1992
Small cell neuroendocrine carcinoma of the vaginaR E Joseph, M H Enghardt, D L Doering, et al.
Obstetrics and Gynecology|December 1, 1989
Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinomaD L Doering, D R Barnhill, E B Weiser, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Gynecologic Oncology|November 25, 1998
Metastatic dermatofibrosarcoma protuberans of the vulvaT M Soergel, D L Doering, D O'connor
Journal of Clinical Laboratory Analysis|January 1, 1995
Comparison of cathepsin D determinations in human carcinomas by enzyme immunoassay and immunoradiometric assayR M Shaheen, S Miseljic, D L Doering, et al.
Gynecologic Oncology|September 1, 1996
Vulvar eccrine porocarcinomaW A Katsanis, D L Doering, J R Bosscher, et al.
Gynecologic Oncology|January 1, 1996
Aberrations in normal systemic lipid metabolism in ovarian cancer patientsC Gercel-Taylor, D L Doering, F B Kraemer, et al.
Gynecologic Oncology|January 4, 2001
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancerC Tecimer, D L Doering, L J Goldsmith, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 10, 2001
Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancerC. Tecimer, D. L. Doering, L. J. Goldsmith, et al.
Gynecologic Oncology|April 1, 1997
Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell linesR K Gibb, D D Taylor, T Wan, et al.
Cancer|February 15, 1996
Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteriJ S Sanfilippo, S Miseljic, A R Yang, et al.
Cancer|August 15, 1992
Small cell neuroendocrine carcinoma of the vaginaR E Joseph, M H Enghardt, D L Doering, et al.
Obstetrics and Gynecology|December 1, 1989
Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinomaD L Doering, D R Barnhill, E B Weiser, et al.
Pageof 2